Significantly, these Aβ42-induced impairments in mitochondrial function were completely blocked by pharmacological inhibition of CaMKK2, which suggests that CaMKK2 inhibition may have therapeutic potential for treating Alzheimer’s disease. This evidence concerns the gene CAMKK2 and early-onset autosomal dominant Alzheimer disease.